Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Nimotuzumab with Chemotherapy in R/M HNSCC
NCT04882462Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- May 2021
- Primary completion
- Nov 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of sintilimab, nimotuzumab in head and neck squamous cell carcinoma (HNSCC), sponsored by First Affiliated Hospital of Soochow University. Status: unknown.
02
Drugs
sintilimabnimotuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04882462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04882462.